What were Tempest Therapeutics' revenue and net loss for Q2 2025, and how do they compare to prior quarters?

Answer to the question

The brief excerpt you shared does not include the actual revenue or net‑loss figures for Tempest Therapeutics’ second quarter of 2025, nor does it give the comparable numbers for earlier quarters. The full press‑release (or the accompanying SEC Form 8‑K) would list those amounts, and without them we can’t quote the exact numbers.

What to do next (trading‑focused)

1. Pull the complete earnings release – Tempest’s investor‑relations site or the SEC’s EDGAR database will have the Q2 2025 results, including total revenue (likely a modest figure for a clinical‑stage biotech) and the net loss (which historically has been in the low‑double‑digit‑million‑dollar range).

2. Benchmark against prior periods – Once you have the numbers, compare Q2 2025 to Q1 2025 and Q2 2024:

* If revenue is up and the net loss has narrowed, the company is moving closer to cash‑flow breakeven—a positive signal that could tighten the stock’s valuation multiple and invite short‑term buying on breakout‑type technical patterns.

* If revenue is flat or down and the net loss has widened, the market may price‑in a deeper cash‑burn, keeping the stock in a down‑trend channel and potentially reinforcing bearish technical momentum.

Trading implication

Without the exact figures, any position would be speculative. Secure the precise Q2 2025 numbers first; then, if the trend shows improving top‑line performance and a contracting loss, consider a long‑biased play on any technical support‑bounce (e.g., buying near the 20‑day moving average if the price is holding) with a stop just below that average. Conversely, if the loss is expanding and revenue is stagnant, a short‑biased approach—targeting the next technical resistance level—may be more appropriate, again using a tight stop to limit downside if the company releases unexpected positive data (e.g., a promising trial read‑out) later in the quarter.

In short, obtain the full earnings release to confirm the revenue and net‑loss numbers, then let the fundamental trend (improving vs. deteriorating) drive your technical entry/exit strategy.